JOSÉ ÁNGEL
HERNÁNDEZ RIVAS
Profesor asociado de Ciencias de la Salud
Hospital Morales Meseguer
Murcia, EspañaPublicaciones en colaboración con investigadores/as de Hospital Morales Meseguer (10)
2024
-
Correction to: Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (Scientific Reports, (2022), 12, 1, (13057), 10.1038/s41598-022-17271-3)
Scientific Reports
-
Low dose lenalidomide versus placebo in non-transfusion dependent patients with low risk, del(5q) myelodysplastic syndromes (SintraREV): a randomised, double-blind, phase 3 trial
The Lancet Haematology, Vol. 11, Núm. 9, pp. e659-e670
-
Omicron SARS-CoV-2 infection management and outcomes in patients with hematologic disease and recipients of cell therapy
Frontiers in Oncology, Vol. 14
2023
2022
-
A simple score to predict early severe infections in patients with newly diagnosed multiple myeloma
Blood cancer journal, Vol. 12, Núm. 4, pp. 68
-
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA
Scientific Reports, Vol. 12, Núm. 1
-
IBRORS-MCL study: a Spanish retrospective and observational study of relapsed/refractory mantle-cell lymphoma treated with ibrutinib in routine clinical practice
International Journal of Hematology, Vol. 116, Núm. 3, pp. 381-392
2021
-
Real-World Characteristics and Outcome of Patients Treated With Single-Agent Ibrutinib for Chronic Lymphocytic Leukemia in Spain (IBRORS-LLC Study)
Clinical Lymphoma, Myeloma and Leukemia, Vol. 21, Núm. 12, pp. e985-e999
2017
-
Risk of thrombosis according to need of phlebotomies in patients with polycythemia vera treated with hydroxyurea
Haematologica, Vol. 102, Núm. 1, pp. 103-109
2016
-
Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera
British Journal of Haematology, Vol. 172, Núm. 5, pp. 786-793